SCHEMBL2064448

SCHEMBL2064448

OCc1c(F)cccc1-c1ccc2nc(-c3ccc(F)c(F)c3)cn2c1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 7/20 0.60
KCNH2 Q12809 2/20 0.48
CYP2C9 P11712 1/20 0.48
ALDH1A3 P47895 6/20 0.43
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LRRK2 Q5S007 4/20 0.42
ABL1 P00519 3/20 0.42
ALDH1A2 O94788 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3432775 0.92 NR4A2 (0.58) NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1
SCHEMBL2064109 0.89 NR4A2 (0.60) NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1
SCHEMBL2063551 0.88 NR4A2 (0.77) NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1
SCHEMBL2063098 0.88 NR4A2 (0.63) NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1
SCHEMBL2065198 0.88 NR4A2 (0.63) NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1
SCHEMBL2063617 0.88 NR4A2 (0.54) NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1
SCHEMBL2064621 0.87 NR4A2 (0.57) NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1
SCHEMBL2062962 0.87 NR4A2 (0.79) NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1
SCHEMBL2063498 0.87 NR4A2 (0.61) NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1
SCHEMBL2064088 0.87 NR4A2 (0.61) NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262803-B1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-10-17 EP claimed
US-8148370-B2 Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-04-03 US claimed
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US claimed
EP-2262803-B1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-10-17 EP disclosed
US-8148370-B2 Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-04-03 US disclosed
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN NR4A2 1531/4885KCNH2 1429/4885CYP2C9 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.